Recursion Pharmaceuticals

Yahoo Finance • 8 days ago

Cathie Wood Keeps Dumping Tesla Stock -- Here is Why

This article first appeared on GuruFocus. Cathie Wood's ARK Invest once again trimmed its stake in Tesla (NASDAQ:TSLA) while increasing exposure to crypto-related stocks, according to a Thursday filing with the SEC. The fund sold 23,110... Full story

Yahoo Finance • 10 days ago

Stocks making the biggest moves midday: Oracle, Jabil, Paramount, Texas Pacific & more

Check out the companies making the biggest moves in midday trading: Texas Pacific Land — Shares of the large Texas landowner jumped 8% after it struck a deal with Bolt Data & Energy to develop large-scale data center campuses on properties... Full story

Yahoo Finance • 10 days ago

Stocks making the biggest moves premarket: Netflix, Amazon, Lennar, General Mills & more

Check out the companies making the biggest moves in premarket trading: Warner Bros. Discovery , Netflix , Paramount Skydance — Warner Bros. Discovery's board unanimously recommended that shareholders reject Paramount Skydance's takeover bi... Full story

Yahoo Finance • 19 days ago

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 weeks off therapy (week 25 of the study), 8... Full story

Yahoo Finance • 20 days ago

1 Nvidia-Backed Artificial Intelligence Stock to Buy Hand Over Fist in 2026

Key Points Nvidia holds stock in CoreWeave and has committed to a $6.3 billion investment in the company. CoreWeave builds AI data centers and rents out compute capacity to the hyperscalers. CoreWeave trades at a discount to smaller peers... Full story

Yahoo Finance • 26 days ago

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing... Full story

Yahoo Finance • last month

A Look at Recursion Pharmaceuticals’s Valuation Following New CEO, Narrowed Losses, and Milestone Partnership Payment

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also noted the recent milestone payment fro... Full story

Yahoo Finance • last month

Recursion (RXRX) Jumps 8% on Bargain-Hunting

We recently published 10 Big Names Crushing the Market. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best-performing stocks on Friday. Recursion Pharmaceuticals soared by 8.31 percent on Friday to close at $4.17 apiece as i... Full story

Yahoo Finance • last month

Is Recursion Pharmaceuticals a Meme Stock?

Key Points Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a buy. 10 stocks we like better... Full story

Yahoo Finance • last month

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

MarketNewsUpdatesNews Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased consumer focus on preventive and longevity-focu... Full story

Yahoo Finance • 2 months ago

Will Recursion Pharmaceuticals’ (RXRX) New CEO Accelerate Its AI Ambitions and Strategic Partnerships?

In recent days, Recursion Pharmaceuticals announced a major leadership transition appointing Najat Khan, Ph.D., as CEO effective January 1, 2026, while also securing a milestone payment from Roche and Genentech for delivering a whole-genom... Full story

Yahoo Finance • 2 months ago

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of neurological diseasesWith this achievement, Rec... Full story

Yahoo Finance • 2 months ago

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board of Directors has unanimously approved... Full story

Yahoo Finance • 2 months ago

AI in Biotechnology Market to Reach $11.4 Billion by 2030

BCC Research LLC “BCC Research analyzes how AI-driven discovery tools, predictive analytics, and scalable cloud platforms are transforming biotechnology's future.” Boston, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Artificial intelligence (AI) is... Full story

Yahoo Finance • 2 months ago

Jim Cramer on Recursion Pharmaceuticals: “Now, It’s a Meme Stock”

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer was focused on recently. A caller asked if the stock lives up to the hype or if it is too speculative. Cramer replied: “Okay, I had Recursion on when they were... Full story

Yahoo Finance • 2 months ago

Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings

We recently published 10 Big Names Beating Wall Street at its Own Game. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Monday. Recursion Pharmaceuticals soared by 13.99 percent on Monday to close at $6.68 a... Full story

Yahoo Finance • 2 months ago

Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event

We recently published 10 Stocks Stealing Today’s Spotlight; 5 on All-Time Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Wednesday. Recursion Pharmaceuticals extended its winning streak to a third st... Full story

Yahoo Finance • 2 months ago

4 Healthcare Stocks to Buy Now

Key Points Two gene-editing companies are advancing therapies, with one generating commercial sales and both approaching major regulatory milestones. An AI drug discovery company is approaching multiple trial readouts in late 2025 that co... Full story

Yahoo Finance • 3 months ago

Recursion Pharmaceuticals (RXRX) Shares Cross Above 200 DMA

In trading on Wednesday, shares of Recursion Pharmaceuticals Inc (Symbol: RXRX) crossed above their 200 day moving average of $5.83, changing hands as high as $5.89 per share. Recursion Pharmaceuticals Inc shares are currently trading up... Full story

Yahoo Finance • 3 months ago

Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory

We came across a bullish thesis on Recursion Pharmaceuticals, Inc. on Emil Hartela Investing’s Substack by Emil. In this article, we will summarize the bulls’ thesis on RXRX. Recursion Pharmaceuticals, Inc.'s share was trading at $4.6300 a... Full story